TScan Therapeutics (TCRX) Short term Debt (2023 - 2026)
TScan Therapeutics' Short term Debt came in at $11.71 million for Q2 2026.
Powered by 
Analysis
TScan Therapeutics (TCRX) Short term Debt (2023 - 2026) Analysis & Trends
At the end of FY2023, TScan Therapeutics' Short term Debt was $3.35 million.
- The Q2 2026 figure represents the lowest quarterly Short term Debt since Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn |
| 10 | TScan Therapeutics | 25.99 Mn | -539.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.71 Mn |
| Jun 30, 2024 | 10.34 Mn |
| Mar 31, 2024 | 6.80 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 1.11 Mn |
API Access
TScan Therapeutics Short term Debt API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=short-term-debt&ticker=TCRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "short-term-debt", "ticker": "TCRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=short-term-debt&ticker=TCRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();